<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168776</url>
  </required_header>
  <id_info>
    <org_study_id>SIN-US-001</org_study_id>
    <nct_id>NCT03168776</nct_id>
  </id_info>
  <brief_title>PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease</brief_title>
  <official_title>A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients With Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sino Medical Sciences Technology Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Vascular LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sino Medical Sciences Technology Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA&#xD;
      Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the&#xD;
      XIENCE or Promus durable polymer coronary stents.&#xD;
&#xD;
      This prospective, global, multi-center, randomized 2:1, single blind study will enroll up to&#xD;
      1632 subjects at up to 130 investigational sites in North America, Japan, and Europe.&#xD;
      Subjects will have clinical follow-up in-hospital and at 30 days, 6 months, 12 months, and 2,&#xD;
      3, 4, and 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>defined as the composite of cardiac death, target vessel related myocardial infarction (TV-MI), and clinically-driven target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term Safety and Efficacy defined as target lesion failure (TLF) between 12 months and 5 years by landmark analysis</measure>
    <time_frame>Between 12 months and 5 years</time_frame>
    <description>TLF is defined as the composite of cardiac death, target vessel related myocardial infarction (TV-MI), and clinically-driven target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>30 days, 6 months, 12 months, and 2, 3, 4, and 5 years</time_frame>
    <description>defined as a composite of all-cause death, myocardial infarction, and target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days, 6 months, 12 months, and 2, 3, 4, and 5 years</time_frame>
    <description>classified as cardiac or non-cardiac, and reported cumulatively and individually</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI)</measure>
    <time_frame>30 days, 6 months, 12 months, and 2, 3, 4, and 5 years</time_frame>
    <description>defined according to the modified Third Universal Definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days, 6 months, 12 months, and 2, 3, 4, and 5 years</time_frame>
    <description>definite or probable (ARC-defined), classified as early, late, or very late</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications (BARC definitions)</measure>
    <time_frame>30 days, 6 months, 12 months, and 2, 3, 4, and 5 years</time_frame>
    <description>evaluated as components and as a composite of BARC Type 3 and 5 bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success</measure>
    <time_frame>30 days, 6 months, 12 months, and 2, 3, 4, and 5 years</time_frame>
    <description>defined as attainment of &lt;30% residual stenosis, as measured by quantitative coronary angiography (QCA) using any percutaneous method [evaluated post-procedure]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>30 days, 6 months, 12 months, and 2, 3, 4, and 5 years</time_frame>
    <description>defined as attainment of &lt;30% residual stenosis of the target lesion measured by QCA using the assigned device [evaluated post-procedure]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>30 days, 6 months, 12 months, and 2, 3, 4, and 5 years</time_frame>
    <description>defined as lesion success without the occurrence of in-hospital MACE [evaluated in-hospital]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven target lesion revascularization (TLR)</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4, and 5 years</time_frame>
    <description>[evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven target vessel revascularization (TVR)</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4, and 5 years</time_frame>
    <description>[evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4, and 5 years</time_frame>
    <description>defined as cardiac death, target vessel-related MI, or clinically-driven target vessel revascularization [evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>30 days, 6 months, and 2, 3, 4, and 5 years</time_frame>
    <description>defined as cardiac death, target vessel-related MI, or clinically-driven target lesion revascularization [evaluated in hospital and at 30 days, 6 months, and 2, 3, 4 and 5 years]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1632</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>BuMA Supreme Coronary Stent System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience or Promus Everolimus Stent System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BuMA Supreme DES</intervention_name>
    <description>Implant BuMA Supreme stent only</description>
    <arm_group_label>BuMA Supreme Coronary Stent System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience or Promus DES</intervention_name>
    <description>Implant XIENCE family or Promus family only</description>
    <arm_group_label>Xience or Promus Everolimus Stent System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is a male or non-pregnant female ≥20 years of age.&#xD;
&#xD;
          2. The patient has symptomatic ischemic heart disease, including chronic stable angina&#xD;
             (and/or objective evidence of myocardial ischemia on functional study or invasive&#xD;
             fractional flow reserve [FFR] measurement) or acute coronary syndromes (UA or NSTEMI),&#xD;
             that requires elective or urgent percutaneous coronary intervention (PCI).&#xD;
&#xD;
          3. The patient is an acceptable candidate for percutaneous coronary intervention (PCI)&#xD;
             with drug-eluting stents, and for emergent coronary bypass graft (CABG) surgery.&#xD;
&#xD;
          4. The patient is willing to comply with specified follow-up evaluations.&#xD;
&#xD;
          5. The patient or legally authorized representative has been informed of the nature of&#xD;
             the study, agrees to its provisions, and has been provided written informed consent&#xD;
             approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure. Female patients of childbearing potential must have a&#xD;
             negative pregnancy test done within 7 days prior to index procedure per site standard&#xD;
             test.&#xD;
&#xD;
          2. Patients with a history of bleeding diathesis or coagulopathy, contraindications to&#xD;
             anti-platelet and/or anticoagulant therapy, or who will refuse transfusion.&#xD;
&#xD;
          3. Patients who are receiving or will require chronic anticoagulation therapy for any&#xD;
             reason.&#xD;
&#xD;
          4. Known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, ADP&#xD;
             receptor antagonists (clopidogrel, prasugrel, ticagrelor, ticlopidine), cobalt&#xD;
             chromium, 316L stainless steel or platinum, sirolimus or its analogues, and/or&#xD;
             contrast sensitivity that cannot be adequately pre-medicated.&#xD;
&#xD;
          5. ST-segment elevation myocardial infarction (STEMI) at index presentation or within 7&#xD;
             days prior to randomization.&#xD;
&#xD;
          6. Known LVEF &lt;30% or cardiogenic shock requiring pressors or mechanical circulatory&#xD;
             assistance (e.g., intra-aortic balloon pump, left ventricular assist device, other&#xD;
             temporary cardiac support blood pump).&#xD;
&#xD;
          7. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) &lt;30&#xD;
             mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation or&#xD;
             Cockcroft-Gault formula) or dialysis at the time of screening.&#xD;
&#xD;
          8. Target vessel percutaneous coronary intervention with stent placement in the previous&#xD;
             3 months.&#xD;
&#xD;
          9. Planned elective surgery that would require discontinuation of DAPT within 6 months of&#xD;
             the index procedure.&#xD;
&#xD;
         10. Past or pending heart or any other organ transplant, or on the waiting list for any&#xD;
             organ transplant.&#xD;
&#xD;
         11. Patients who are receiving immunosuppressant therapy, or who have known&#xD;
             immunosuppressive or severe autoimmune disease that will require chronic&#xD;
             immunosuppressive therapy. NOTE: Corticosteroid use is permitted.&#xD;
&#xD;
         12. Known other medical illness or known history of substance abuse that may cause&#xD;
             non-compliance with the protocol, confound data interpretation, or is associated with&#xD;
             a life expectancy of less than 1 year.&#xD;
&#xD;
         13. Current participation in another investigational drug or device study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B Leon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Interventional Vascular Therapy - Columbia University Medical Center / New York-Presbyterian Hospital, United States</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean Kereiakes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital Physicians - Ohio Heart &amp; Vascular, United States</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Windecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital Department for Cardiology, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura General Hospital, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dignity Health - Mercy Gilbert Medical Center / Chandler Regional Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smidt Heart Institute Cedars-Sinai Maedical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Washington HWospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Hospital East/Daniel Heart and Vascular Center</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular Consultants</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediQuest Research Group Inc.</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of Northwest Florida</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krannert Institute of Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Brownsboro Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital d.b.a. McLaren Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Heart</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essential Health</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North MS Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Health Research Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of Delaware Valley</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center / New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Ohio Heart</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Hospital</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berks Cardiologists, Ltd.</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnMed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cardiovascular Consultants</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winchester Medical Center</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg Genk</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Hospital</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N-2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B-1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kanagawa</city>
        <state>Kamakura City</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCL</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigación Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva HUG, Clinic for Cardiology</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

